- Home
- AARD vs CATX Comparison
AARD vs CATX Comparison
Compare AARD & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AARD
- CATX
- Stock Information
- Founded
- AARD 2017
- CATX 1983
- Country
- AARD United States
- CATX United States
- Employees
- AARD N/A
- CATX N/A
- Industry
- AARD Biotechnology: Pharmaceutical Preparations
- CATX Medical/Dental Instruments
- Sector
- AARD Health Care
- CATX Health Care
- Exchange
- AARD Nasdaq
- CATX Nasdaq
- Market Cap
- AARD 231.9M
- CATX 239.0M
- IPO Year
- AARD 2025
- CATX N/A
- Fundamental
- Price
- AARD $9.91
- CATX $2.09
- Analyst Decision
- AARD Strong Buy
- CATX Strong Buy
- Analyst Count
- AARD 8
- CATX 10
- Target Price
- AARD $30.63
- CATX $12.30
- AVG Volume (30 Days)
- AARD 162.6K
- CATX 2.0M
- Earning Date
- AARD 11-13-2025
- CATX 11-10-2025
- Dividend Yield
- AARD N/A
- CATX N/A
- EPS Growth
- AARD N/A
- CATX N/A
- EPS
- AARD N/A
- CATX N/A
- Revenue
- AARD N/A
- CATX $1,075,000.00
- Revenue This Year
- AARD N/A
- CATX N/A
- Revenue Next Year
- AARD N/A
- CATX N/A
- P/E Ratio
- AARD N/A
- CATX N/A
- Revenue Growth
- AARD N/A
- CATX N/A
- 52 Week Low
- AARD $4.88
- CATX $1.60
- 52 Week High
- AARD $19.58
- CATX $10.06
- Technical
- Relative Strength Index (RSI)
- AARD 39.27
- CATX 29.21
- Support Level
- AARD $9.34
- CATX $2.00
- Resistance Level
- AARD $11.51
- CATX $2.31
- Average True Range (ATR)
- AARD 0.85
- CATX 0.19
- MACD
- AARD -0.01
- CATX -0.04
- Stochastic Oscillator
- AARD 20.39
- CATX 9.09
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.